Synthesis and characterization of Fe₃O₄@SiO₂@PDA@Ag core–shell nanoparticles and biological application on human lung cancer cell line and antibacterial strains

Figures & data

Figure 2. DLS of synthesised Fe₃O₄@SiO₂@PDA@Ag (medium: Water; size, d: 139.1 nm).

Figure 3. Zeta potential distribution image of synthesised Fe₃O₄@SiO₂@PDA@Ag.

Figure 4. FT-IR of (a) Fe₃O₄, (b) Fe₃O₄@SiO₂, (c) Fe₃O₄@SiO₂@PDA, and (d) Fe₃O₄@SiO₂@PDA@Ag nanocomposite.

Figure 5. XRD of Fe₃O₄@SiO₂@PDA@Ag nanocomposite.

Figure 6. EDAX of Fe₃O₄@SiO₂@PDA@Ag nanocomposite.

Figure 7. Stability data of Fe₃O₄@SiO₂@PDA@Ag nanocomposite in water, PBS, acidic and basic buffers.

Figure 8. MTT assay at various concentrations on H1299 cancer cell line; (A) % cell viability of Fe₃O₄@SiO₂@PDA (B) % cell viability of Fe₃O₄@SiO₂@PDA@Ag C) comparison of % cell cytotoxicity of Fe₃O₄@SiO₂@PDA and Fe₃O₄@SiO₂@PDA@Ag.

Figure 9. Microscopic images of the effect of the Fe₃O₄@SiO₂@PDA@Ag nanoparticles on H1299 cancer cell line. (A) Untreated/control (B) at 50 µg/mL.

Figure 10. Cell apoptosis assay at different concentrations of Fe₃O₄@SiO₂@PDA@Ag on H1299 cancer cell line (A) control; 0 µg/mL, (B) 20 µg/mL, (C) 30 µg/mL.

Figure 11. Antibacterial activity of Fe₃O₄@SiO₂@PDA@Ag nanocomposites with increasing concentrations against (A) S. aureus and (B) P. aeruginosa.

Figure 12. Scanning electron micrographs of (A) and (B) untreated P. aeruginosa cells and its EDAX composition (C) and (D) cells treated with Fe₃O₄@SiO₂@PDA@Ag nanocomposites at MIC and its EDAX composition.

Figure 13. Haemolysis assay of Fe₃O₄@SiO₂@PDA@Ag nanoparticle at various concentrations.

Data availability statement

Raw data available on request.